Breast
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Real-World Characteristics of NATALEE and monarchE Eligible Populations - A US Electronic Health Records Analysis
FEATURING
Paolo Tarantino
- 4 views
- September 27, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: ctDNA and Molecular Screening for Target Detection and Treatment Monitoring in mBC
FEATURING
Michail Ignatiadis
- 7 views
- September 26, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Breast Cancer Highlights - KEYNOTE-522, NATALEE, DESTINY-BREAST12, and CAPItello-290
FEATURING
Virginia Kaklamani
- 138 views
- September 23, 2024
- 6
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Top 5 Breast Cancer Abstracts - NATALEE, DESTINY-Breast12, KEYNOTE-522, CAPItello-290 & ICARUS-Breast01
FEATURING
Paolo Tarantino
- 151 views
- September 24, 2024
- 2
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: CAPItello-290 Trial - Capivasertib + Paclitaxel as 1L Treatment for mTNBC
FEATURING
Heather McArthur
- 67 views
- September 24, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Pembro or Placebo + CT in High-Risk Early TNBC - OS Results From KEYNOTE-522
FEATURING
Heather McArthur
- 60 views
- September 24, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: DETECT V trial - Omission of Chemo and Addition of the CDK4/6i Ribociclib in HER2+ and HR+ mBC
FEATURING
Wolfgang Janni
- 7 views
- September 23, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: PROMENADE Trial - Pembro for Early ER-Low/HER2- BC - Real World French Cohort
FEATURING
Francois Cherifi
- 52 views
- September 23, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: DESTINY-Breast06 Trial - HER2-Low and HER2-Ultralow Status Determination in Tumors of Patients With HR+ mBC
FEATURING
Giuseppe Viale
- 10 views
- September 23, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Hypo vs. Normofractionated RT in eBC - 5-Year Results of HypoG-01
FEATURING
Sofia Rivera
- 67 views
- September 20, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Prognostic Role of TILs on OS and Treatment De-Escalation in HER2+ Early BC in the ShortHER Trial
FEATURING
Maria Vittoria Dieci
- 75 views
- September 19, 2024